Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.

Reinhard Dummer,Axel Hauschild,Mario Santinami,Victoria Atkinson,Mario Mandalà,Vanna Chiarion Sileni,James Larkin,Marta Nyakas,C. Dutriaux,Andrew Haydon,Caroline Robert,Dirk Schadendorf,Paola Aimone,Bijoyesh Mookerjee,Catarina D. Campbell,James Garrett,Jan C. Brase,Richard F. Kefford,John M. Kirkwood,Georgina V. Long

Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.

2018

9574Background: In the COMBI-AD trial, adjuvant D + T resulted in a significant relapse-free survival benefit (HR, 0.47 [95% CI, 0.39-0.58]; P < .001) vs pbo in pts with resected stage III BRAF V60...

Keywords:

Gene expression profiling
Placebo
Adjuvant
Immune system
Dabrafenib
Trametinib
Physical therapy
Cancer research
Medicine
survival benefit
in patient
Oncology
Internal medicine
immune gene
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations